Vanguard Group’s Neuropace NPCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $15.3M | Buy |
1,369,276
+171,198
| +14% | +$1.91M | ﹤0.01% | 2684 |
|
|
2025
Q1 | $14.7M | Buy |
1,198,078
+140,783
| +13% | +$1.73M | ﹤0.01% | 2638 |
|
|
2024
Q4 | $11.8M | Buy |
1,057,295
+62,099
| +6% | +$695K | ﹤0.01% | 2862 |
|
|
2024
Q3 | $6.94M | Buy |
995,196
+27,480
| +3% | +$192K | ﹤0.01% | 3123 |
|
|
2024
Q2 | $7.32M | Buy |
967,716
+479,098
| +98% | +$3.62M | ﹤0.01% | 3076 |
|
|
2024
Q1 | $6.45M | Buy |
488,618
+75,512
| +18% | +$997K | ﹤0.01% | 3188 |
|
|
2023
Q4 | $4.26M | Buy |
413,106
+27,021
| +7% | +$279K | ﹤0.01% | 3346 |
|
|
2023
Q3 | $3.76M | Buy |
386,085
+7,898
| +2% | +$76.8K | ﹤0.01% | 3361 |
|
|
2023
Q2 | $1.7M | Buy |
378,187
+81,639
| +28% | +$367K | ﹤0.01% | 3721 |
|
|
2023
Q1 | $1.38M | Buy |
296,548
+22,619
| +8% | +$105K | ﹤0.01% | 3809 |
|
|
2022
Q4 | $408K | Buy |
273,929
+133
| +0% | +$198 | ﹤0.01% | 4156 |
|
|
2022
Q3 | $1.03M | Hold |
273,796
| – | – | ﹤0.01% | 3992 |
|
|
2022
Q2 | $1.36M | Sell |
273,796
-37,172
| -12% | -$184K | ﹤0.01% | 3979 |
|
|
2022
Q1 | $2.55M | Sell |
310,968
-122
| -0% | -$1K | ﹤0.01% | 3862 |
|
|
2021
Q4 | $3.14M | Buy |
311,090
+16,825
| +6% | +$170K | ﹤0.01% | 3860 |
|
|
2021
Q3 | $4.66M | Buy |
294,265
+2,289
| +0.8% | +$36.3K | ﹤0.01% | 3708 |
|
|
2021
Q2 | $6.95M | Buy |
+291,976
| New | +$6.95M | ﹤0.01% | 3400 |
|